Rabisin

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Active ingredient:

Rabies virus glycoprotein

Available from:

Merial Animal Health Limited

ATC code:

QI07AA02

INN (International Name):

Rabies virus glycoprotein

Dosage:

.

Pharmaceutical form:

Suspension for injection

Prescription type:

POM: Prescription Only Medicine as defined in relevant national legislation

Therapeutic group:

Cats, Cattle, Dogs, Horses, Other Mammals, Sheep

Therapeutic area:

rabies virus

Therapeutic indications:

Immunological - Inactivated Vaccine

Authorization status:

Authorised

Authorization date:

2004-08-10

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Rabisin
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle, dogs, horses, cats, mustelids and sheep
.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of cattle, dogs, horses, cats, mustelids and
sheep, to reduce mortality and clinical signs due to
rabies infection.
Immunity has been demonstrated 1 month after primary vaccination, and
has been shown to persist up to the first
booster dose (1 year after primary vaccination).
In cats and dogs immunity has been shown to persist for up to 3 years
following booster vaccination.
4.3 CONTRAINDICATIONS
Do not inject the vaccine subcutaneously in horses. Do not inject the
vaccine intramuscularly in cats and dogs.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Do not vaccinate unhealthy animals
.
Each 1 ml dose of vaccine contains:
ACTIVE SUBSTANCE(S):
Rabies virus glycoproteins
1 IU
ADJUVANT(S):
Aluminium (as hydroxide)
1.7
mg
EXCIPIENT(S):
Excipient
q.s.
1
ml
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_0_
_4_
_/_
_0_
_9_
_/_
_2_
_0_
_1_
_4_
_C_
_R_
_N_
_ _
_7_
_0_
_1_
_6_
_6_
_8_
_2_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
(I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS:
Where a dog or cat was vaccinated before 12 weeks of age, the primary
vaccination sc